Featured Story | By James Waldron Five years may not seem long to turn around a struggling biotech. But that’s the time frame that recently installed Galapagos CEO Paul Stoffels has given himself to reorient the company around his mantra of: “Let’s focus on the patient.” read more |
| |
|---|
|
Top Stories By Annalee Armstrong Investors keenly awaiting one-year safety data from uniQure’s Huntington’s disease gene therapy have rewarded the company with a 20% share bump, as the data showed a clear safety profile. read more By James Waldron RedHill Biopharma will lay off a third of its U.S. commercial team as the Israeli biotech looks to claw back $50 million in savings while eyeing up a deal for an approved gastrointestinal drug. read more By Nick Paul Taylor Novartis is pumping $250 million into neglected tropical disease and malaria elimination R&D, while GSK has pledged $1 billion over 10 years to further innovation in malaria, tuberculosis and HIV. read more By Nick Paul Taylor Christoph Westphal is back with another biotech, joining with scientists including Jonathan Weissman, Ph.D., to work on signals that dictate whether macrophages gobble up cancer cells. The startup, Dem BioPharma, is beginning life with $70 million and former Trillium Therapeutics CEO Jan Skvarka in a leading role. read more By Gabrielle Masson Lauren Wood, former head of corporate communications for biotech Immunomedics, has pleaded guilty to securities fraud after buying stock in the company based on a tip from former boyfriend Usama Malik, Immunomedics’ chief financial officer at the time. read more By Angus Liu For Biogen’s ill-fated Alzheimer’s disease drug Aduhelm, a narrow Medicare reimbursement policy is taking a toll beyond sales. The company has pulled the plug on an observational clinical trial that was meant to collect real-world data on Aduhelm’s use in the U.S. read more By Gabrielle Masson New research shows a one-two hit from an experimental vaccine combo is significantly more effective at fighting off treatment-resistant cancers in animal models than either approach by itself—and the Department Defense is throwing down money to move the science into the clinic. read more By Heather Landi In just the past six months, there have been dramatic shifts in the startup environment. Current trends indicate a market correction is underway. But some venture capital investors say they are excited about this market “reset,” as it represents an opportunity for mission-driven founders to thrive. read more By James Waldron Leukemia is notorious for being very aggressive and hard to eradicate from the body. The culprits are leukemic stem cells—known as “seed” cells—that drive resistance to chemotherapy and can trigger a relapse of the cancer. read more By Andrea Park As ventilators and other respiratory devices became more crucial than ever throughout the COVID-19 pandemic, so too did any safety issues embedded in the machines become more apparent. read more By Eric Sagonowsky So far in the Biden administration, lawmakers haven't been able to come to terms on drug pricing measures. But one issue could be gaining steam in the Senate. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
